Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Wine-Related Cancer Treatment Shows Promise Against Neuroblastomas

By LabMedica International staff writers
Posted on 12 Mar 2009
Resveratrol--the intriguing substance that seems to make red wine heart-healthy--is being proposed for clinical trials later in 2009 as a treatment against neuroblastoma, a type of cancer that affects infants and young children.

Dr. Arthur Polans, professor of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health (UW; Madison, USA) and the UW Paul P. Carbone Comprehensive Cancer Center, has been studying the substance for about five years, and has been using it successfully to treat several types of cancer in mice. His research group has applied for permission to use it to treat neuroblastoma, a nervous-system cancer that mostly affects infants and children.

"Resveratrol is a promising treatment for young children because it's not toxic to healthy cells, only to cancer cells,'' Dr. Polans said. "How do you treat infants without causing other problems in the years to come? That is the kind of question that intrigues us.”

Because it seems to kill cancer kills while leaving healthy tissue alone, resveratrol is also being looked at to treat ocular or uveal melanoma, a cancer of the eye that can lie dormant for many years before metastasizing and becoming fatal. So far, there are no good treatments for melanoma that begins in the colored tissues of the eye; it doesn't respond the same way as melanoma that begins in the skin. "It's one of those rotten cancers,'' Dr. Polans noted. "We don't know what causes it and we don't know how to treat it effectively.”

While the cancers are very different, adults who develop melanoma of the eye have something in common with babies who develop neuroblastoma--they may live for a long time after their diagnosis, so potential treatments shouldn't cause other health problems.

"What neuroblastoma and uveal melanoma have in common is the factor of time,” said Dr. Polans. "Ideally, you'd like to be able to treat them aggressively at first, and then treat them with lower doses of a non-toxic compound over time. Otherwise, you run the risk of damage to vital organs or an increase in secondary tumors.”

So far, the Polans lab has shown that resveratrol shrinks tumors and kills malignant cells in five types of cancer: skin melanoma, breast cancer, neuroblastoma, ocular melanoma and retinoblastoma. A poster outside Dr. Polans' office shows a mouse with a large neuroblastoma tumor that is then shrunken to nothing by resveratrol. "Mice that were treated with resveratrol are healthy, gain weight, and don't seem to have side effects,'' he said, "but when you look at the cancer cells, they're dying.”

Dr. Polans' lab has also done a lot of essential research on resveratrol, developing new forms of the compound that are more potent, and active in the body for longer than the common forms of the substance.

If it shows to be effective, resveratrol will join a large class of cancer-fighting compounds derived from plants, including taxol, which comes from yew trees, and etopside, derived from the mayapple. Resveratrol, which can be derived from grape skins, is also seen as the substance at work in the so-called "French Paradox,'' in which French hearts stay healthy (due to drinking red wine) in spite of all the high fat foods consumed.

"About 70% of new chemotherapeutics are derived from natural products or based on their structures,'' concluded Dr. Polans. "There's a lot of interest worldwide in finding new substances from plants and other natural sources, including microbes from the soil and a variety of species from the ocean.”

Related Links:

University of Wisconsin School of Medicine and Public Health



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.